Wednesday, 21 Aug 2019

You are here

Weight Loss Improves Psoriasis

Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition. (Citation source: http://buff.ly/2j8zHWo),

They examined long-term outcomes of weight loss in 56 obese patients with a mean PASI score of 5.4 and a body mass index of 34.4 kg/m2. Patients were randomized to a low-energy diet (LED) group or a control group given general advice to eat healthy foods.

The diet consisted of 8 weeks of a low-energy liquid (fortified drinks and soups) diet (800-1,000 kcal) followed by 8 weeks in which regular foods were reintroduced at 1,200 kcal/day. Patients underwent a 64-week weight-loss program consisting of an initial 16-week randomized phase with an LED for 8 weeks and 8 weeks of normal food intake combined with 2 LED products/day, followed by a 48-week period of weight maintenance with the latter diet. After the randomization phase, the control group received the same 8 + 8-week LED intervention, and all patients were then followed for 48 weeks while on the weight-loss maintenance diet.

After the initial 16-wk LED-only period, the mean weight loss was −15.0 kg along with a decrease in PASI (-2.3) and DLQI (−2.3). At week 64, the mean weight loss compared with baseline was −10.1 kg and the PASI and DLQI reductions were maintained at −2.9 and −1.9, respectively.

Long-term weight loss in patients with psoriasis has long-lasting positive effects on the severity of psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.

Biologic Therapy Improves Psoriasis and Reduces CV Inflammation

Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy? JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary inflammation associated with cardiovascular outcomes. Patients not receiving biologic therapy had no change in perivascular fat attenuation index at 1 year.

Joint Surgery Rates Remain High in Psoriatic Arthritis

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.